tetano
Editor, Senior Moderator
Influenza Other Respi Viruses. 2011 Sep 28. doi: 10.1111/j.1750-2659.2011.00290.x. [Epub ahead of print]
Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety.
Tavana S, Argani H, Gholamin S, Razavi SM, Keshtkar-Jahromi M, Talebian AS, Moghaddam KG, Sepehri Z, Azad TM, Keshtkar-Jahromi M.
Source
Clinical Research & Development Center, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran Center for AIDS Research, Division of Infectious Disease, Stanford University School of Medicine, Stanford, CA, USA Department of Internal Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran Union Memorial Hospital, University of Maryland, Baltimore, MD, USA.
Abstract
Please cite this paper as: Tavana et al. (2011) Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750-2659.2011.00290.x. Background Sarcoidosis is an inflammatory, granulomatous disorder of unknown etiology. The role of cellular and humoral immune systems in this disease is unclear, whereas dysregulation of the immune system is suggested. Patients with sarcoidosis show diverse responses while exposed to various antigens. Although influenza vaccination is recommended in pulmonary sarcoidosis, its efficacy and safety has not been investigated. Objectives To evaluate safety and immunogenicity of influenza vaccine in patients with sarcoidosis. Patients/Methods Influenza vaccination was performed in 23 eligible patients with sarcoidosis (SP) and 26 healthy controls (HC). Antibody titers against H1N1, H3N2, and B influenza virus antigens were evaluated just before and 1 month after vaccination. Patients were followed for 6 months to assess vaccine safety. Results Serological response and magnitude of changes in antibody titers against influenza vaccine antigens were comparable between SPs and HCs. Women showed a better serological response against B antigen (P = 0?034) than men. Twenty-four-hour urine calcium was associated with antibody response against H1N1 [correlation coefficient (CC) = 0?477, P = 0?003] and H3N2 (CC = 0?352, P = 0?028) antigens. Serum angiotensin-converting enzyme correlated negatively with antibody response against B antigen (CC = -0?331, P = 0?040). Higher residual volume was associated with fewer rises in antibody titer against H3N2 antigen (CC = -0?377, P = 0?035). No major adverse events or disease flare-up was observed during follow-up. Conclusions In this study, influenza vaccination did not cause any major adverse event in SPs, and their serological response was equal to HCs. Studies with larger sample size and a broader selection of subjects could help validate the results of this study.
? 2011 Blackwell Publishing Ltd.
PMID:
21955954
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21955954
Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety.
Tavana S, Argani H, Gholamin S, Razavi SM, Keshtkar-Jahromi M, Talebian AS, Moghaddam KG, Sepehri Z, Azad TM, Keshtkar-Jahromi M.
Source
Clinical Research & Development Center, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran Center for AIDS Research, Division of Infectious Disease, Stanford University School of Medicine, Stanford, CA, USA Department of Internal Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran Union Memorial Hospital, University of Maryland, Baltimore, MD, USA.
Abstract
Please cite this paper as: Tavana et al. (2011) Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750-2659.2011.00290.x. Background Sarcoidosis is an inflammatory, granulomatous disorder of unknown etiology. The role of cellular and humoral immune systems in this disease is unclear, whereas dysregulation of the immune system is suggested. Patients with sarcoidosis show diverse responses while exposed to various antigens. Although influenza vaccination is recommended in pulmonary sarcoidosis, its efficacy and safety has not been investigated. Objectives To evaluate safety and immunogenicity of influenza vaccine in patients with sarcoidosis. Patients/Methods Influenza vaccination was performed in 23 eligible patients with sarcoidosis (SP) and 26 healthy controls (HC). Antibody titers against H1N1, H3N2, and B influenza virus antigens were evaluated just before and 1 month after vaccination. Patients were followed for 6 months to assess vaccine safety. Results Serological response and magnitude of changes in antibody titers against influenza vaccine antigens were comparable between SPs and HCs. Women showed a better serological response against B antigen (P = 0?034) than men. Twenty-four-hour urine calcium was associated with antibody response against H1N1 [correlation coefficient (CC) = 0?477, P = 0?003] and H3N2 (CC = 0?352, P = 0?028) antigens. Serum angiotensin-converting enzyme correlated negatively with antibody response against B antigen (CC = -0?331, P = 0?040). Higher residual volume was associated with fewer rises in antibody titer against H3N2 antigen (CC = -0?377, P = 0?035). No major adverse events or disease flare-up was observed during follow-up. Conclusions In this study, influenza vaccination did not cause any major adverse event in SPs, and their serological response was equal to HCs. Studies with larger sample size and a broader selection of subjects could help validate the results of this study.
? 2011 Blackwell Publishing Ltd.
PMID:
21955954
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21955954